Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT01177371 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Start date: March 1988
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methylprednisolone, and methotrexate after transplant may stop this from happening. PURPOSE: This clinical trial studies high-dose busulfan and high-dose cyclophosphamide followed by donor bone marrow transplant in treating patients with leukemia, myelodysplastic syndrome, multiple myeloma, or recurrent Hodgkin or Non-Hodgkin lymphoma.

NCT ID: NCT01164696 Completed - Clinical trials for Non-Hodgkin Lymphoma

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Start date: August 2007
Phase: N/A
Study type: Observational

The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

NCT ID: NCT01164475 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Start date: October 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.

NCT ID: NCT01164345 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Mozobil for Autologous Stem Cell Mobilization

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.

NCT ID: NCT01158274 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RO4929097 together with chemotherapy may kill more tumor cells.

NCT ID: NCT01158118 Completed - Multiple Myeloma Clinical Trials

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Start date: April 1, 2011
Phase: Phase 2
Study type: Interventional

This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.

NCT ID: NCT01155817 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Start date: August 2010
Phase: Phase 1
Study type: Interventional

PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

NCT ID: NCT01153971 Completed - Clinical trials for Non-Hodgkin's Lymphoma

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

NCT ID: NCT01149668 Completed - Multiple Myeloma Clinical Trials

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.

NCT ID: NCT01145495 Completed - Clinical trials for Ann Arbor Stage III Grade 2 Follicular Lymphoma

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Start date: June 15, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lenalidomide and rituximab work in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide together with rituximab may kill more cancer cells.